Ipilimumab plus nivolumab for advanced melanoma

The Lancet Oncology

Volumn 17, Issue 11, 2016, Pages 1471-1472

  Hassel, Jessica C ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; NIVOLUMAB; MONOCLONAL ANTIBODY;

ADVANCED CANCER; CANCER GROWTH; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEASUREMENT ACCURACY; METASTATIC MELANOMA; NOTE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; MELANOMA;

ANTIBODIES, MONOCLONAL; HUMANS; IPILIMUMAB; MELANOMA;

EID: 85019575576     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30409-0     Document Type: Note

References (9)

1. 1 Hodi, FS, O'Day, SJ, McDermott, DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
2. 2 Schadendorf, D, Hodi, FS, Robert, C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33 (2015), 1889–1894.
3. 3 Robert, C, Long, GV, Brady, B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2015), 320–330.
4. 4 Robert, C, Ribas, A, Hamid, O, et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Proc Am Soc Clin Oncol, 34(suppl), 2016 abstr 9503.
5. 5 Larkin, J, Chiarion-Sileni, V, Gonzalez, R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 1270–1321.
6. 6 Wolchok, JD, Kluger, H, Callahan, MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369 (2013), 122–133.
7. 7 Sznol M, Callahan MK, Kluger H, et al. Updated survival, response and safety data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) and ipilimumab (IPI) in advanced melanoma. Society for Melanoma Research Annual Meeting; San Francisco, California, USA; Nov 18–21, 2015.
8. 8 Hodi, FS, Chesney, J, Pavlick, AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol, 2016 published online Sept 8. http://dx.doi.org/10.1016/S1470-2045(16)30366-7.
9. 9 Postow, MA, Chesney, J, Pavlick, AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372 (2015), 2006–2017.